{"schema_version":"secwatch.filing_event.v1","accession":"0001096906-21-001784","form_type":"8-K","ticker":"AXIM","cik":"0001514946","company_name":"AXIM BIOTECHNOLOGIES, INC.","filed_at":"2021-08-04T23:59:59+00:00","discovered_at":"2026-05-14T18:04:18.349576+00:00","generated_at":"2026-06-29T22:33:24.960365+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"AXIM Biotech signs binding term sheet to acquire FDA-cleared dry eye tests, paying 7M shares","bullets":["AXIM to acquire two FDA-cleared dry eye diagnostic tests from Advanced Tear Diagnostics for 7M restricted shares.","Tests include 10-minute lactoferrin assay and ocular IgE test; commercial launch targeted for early 2022.","Dry eye disease affects ~20M in US; global DED diagnostics market projected at $9.8B by 2030.","Binding term sheet in effect; definitive agreement and closing expected by October 1, 2021."],"urls":{"canonical":"https://secwatch.observer/filing/0001096906-21-001784","json":"https://secwatch.observer/filing/0001096906-21-001784.json","markdown":"https://secwatch.observer/filing/0001096906-21-001784.md","text":"https://secwatch.observer/filing/0001096906-21-001784.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1514946/000109690621001784/0001096906-21-001784-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1514946/000109690621001784/axim-20210802.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-29T22:33:24.960365+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}